The sequential improvement in gross margin from 12.1% in 2025Q4 to 14.7% in 2026Q2 suggests that pricing actions are beginning to offset raw material inflation, but the operating margin of 2.0% remains well below the 15.4% gross margin peak seen in 2024Q2. This implies that fixed overhead and SG&A costs are absorbing the incremental gross profit, as SG&A rose 14.4% year-over-year in the latest quarter. The persistent negative net margin, despite positive operating income, indicates that non-operating items such as interest and other charges continue to weigh heavily on the bottom line, warranting close monitoring of whether volume growth can translate into sustainable earnings.

The ten-quarter average ROIC of approximately 0.0% suggests that the company is not generating economic profit, and the negative ROE of -9.0% in the latest quarter reflects the erosion of equity from cumulative losses. The slight improvement in ROIC to 0.5% in 2026Q2 from -0.7% in 2025Q4 is encouraging but remains far below the levels needed to justify the capital employed. This pattern indicates that the company's returns are highly sensitive to the chemical cycle, and investors should monitor whether the recent volume recovery can drive ROIC above the cost of capital, which would signal a genuine turnaround rather than a temporary bounce.

The reduction in DIO from 69 days to 58 days over the past year suggests that Huntsman is managing inventory more tightly, likely in response to softer demand, which has helped free up cash. However, DSO has remained relatively stable around 45-50 days, indicating that the company is not extending credit terms to customers to drive sales, which is a positive sign for cash collection. The overall CCC improvement from 68 days to 49 days is a notable efficiency gain, but it may also reflect destocking rather than structural improvement, so investors should watch whether this trend persists as volumes recover.

The D/E ratio has increased steadily over the past two years, partly because equity has been eroded by cumulative losses, which makes the leverage appear higher than if earnings were stable. Interest coverage of 1.48 in 2026Q2 is a significant improvement from the negative readings in 2025Q4 and 2025Q2, suggesting that operating income is now sufficient to cover interest expenses, but the margin of safety is thin. The D/EBITDA ratio of 22.53 in 2026Q2, though down from 80.03 in 2025Q4, remains elevated due to depressed EBITDA, indicating that the company's debt load is heavy relative to current cash generation, and any further earnings weakness could strain debt service.

The quick ratio of 0.78 in 2026Q2 suggests that Huntsman's liquid assets are insufficient to cover current liabilities if inventory cannot be converted to cash quickly, which is a concern given the cyclical nature of chemical demand. The decline in cash reserves from $552M to $346M over the past two years, combined with the persistent negative net income, indicates that the company is consuming cash to fund operations and dividends. While the current ratio remains above 1.0, the trend is concerning, and investors should monitor whether the recent volume recovery can generate sufficient cash flow to rebuild the liquidity buffer.